SSRIs

The leading — though admittedly incomplete — model of depression is the monoamine hypothesis: depressive symptoms are linked to too little signaling by monoamine neurotransmitters, especially serotonin (5-HT), in the brain circuits that regulate mood, sleep, appetite, and anxiety. SSRIs are built directly on this idea: raise serotonin in the synapse, relieve the symptoms.

Here is the machinery. When a serotonin neuron fires, it releases 5-HT into the synaptic cleft, where it activates receptors on the next neuron. The signal is then switched off by the serotonin transporter (SERT), a pump on the sending neuron that vacuums serotonin back up for reuse (reuptake). SSRIs block SERT, so serotonin lingers in the cleft and keeps stimulating the receiving neuron. They are "selective" because they leave the norepinephrine and dopamine pumps largely alone.

The single most important teaching point about SSRIs is the delayed onset. The reuptake block is immediate — synaptic serotonin rises within hours of the first dose — yet the antidepressant effect takes 4 to 6 weeks (sometimes longer). If the drug works instantly at the molecular level, why the lag?

The accepted explanation is neuroadaptation. That first flood of serotonin also hits inhibitory 5-HT1A autoreceptors on the neuron itself, which sense "enough serotonin out there" and *throttle the neuron’s own firing* — blunting the net effect at first. Over several weeks these autoreceptors down-regulate and desensitize, firing normalizes, and slower downstream changes (receptor sensitivity, increased neuroplasticity/BDNF) produce the durable lift in mood. The clinical consequence is critical: a patient must be told to keep taking a drug that "isn’t working yet," and the early weeks carry a specific danger — energy and initiative often return before mood does, so a previously immobilized patient may gain the drive to act on lingering hopelessness. That is the mechanistic root of the suicidality warning.

Serotonin is not a brain-only molecule. Most of the body’s serotonin lives in the gut, and it is stored in platelets — so raising serotonergic tone has predictable effects far from the mood circuits. In the GI tract the extra serotonin causes early nausea and diarrhea (often transient). Effects on serotonergic sexual pathways cause sexual dysfunction. In platelets, SSRIs deplete the serotonin needed for clumping, so bleeding risk rises — additive with NSAIDs and anticoagulants.

Two mirror-image dangers bracket the therapeutic window. Too much serotonergic activity — usually when an SSRI is combined with another serotonergic drug — causes serotonin syndrome, a potentially fatal storm of altered mental status, autonomic instability, and neuromuscular hyperactivity (the classic clue is clonus and hyperreflexia, worse in the legs). And the sudden loss of serotonin when a drug is stopped abruptly — after the brain has adapted to high levels — causes a discontinuation syndrome (dizziness, flu-like feelings, and the characteristic electric-shock "brain zaps").